You can:
Name | Delta-type opioid receptor |
---|---|
Species | Homo sapiens (Human) |
Gene | OPRD1 |
Synonym | D-OR-1 DOR opioid receptor OP1 DOP [ Show all ] |
Disease | Cough Overactive bladder disorder Bladder disease Moderate-to-severe pain Diarrhea-predominant IBS [ Show all ] |
Length | 372 |
Amino acid sequence | MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA |
UniProt | P41143 |
Protein Data Bank | 4rwd, 4rwa, 4n6h |
GPCR-HGmod model | P41143 |
3D structure model | This structure is from PDB ID 4rwd. |
BioLiP | BL0303696,BL0303697, BL0265712, BL0265705,BL0265706,BL0265707,, BL0303699,BL0303701, BL0303698,BL0303700 |
Therapeutic Target Database | T58992 |
ChEMBL | CHEMBL236 |
IUPHAR | 317 |
DrugBank | BE0000420 |
Name | naloxone |
---|---|
Molecular formula | C19H21NO4 |
IUPAC name | (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one |
Molecular weight | 327.38 |
Hydrogen bond acceptor | 5 |
Hydrogen bond donor | 2 |
XlogP | 2.1 |
Synonyms | NSC 70413 C07252 Prestwick2_000111 D0X3FX UNII-36B82AMQ7N [ Show all ] |
Inchi Key | UZHSEJADLWPNLE-GRGSLBFTSA-N |
Inchi ID | InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1 |
PubChem CID | 5284596 |
ChEMBL | CHEMBL80 |
IUPHAR | 1638, 1676 |
BindingDB | 54795, 50000788 |
DrugBank | DB01183 |
Structure | |
Lipinski's druglikeness | This ligand satisfies Lipinski's rule of five. |
Parameter | Value | Reference | Database source |
---|---|---|---|
N/A | N/A | DrugBank | |
% recovery | 0.0 - | PMID1320121 | ChEMBL |
% recovery | 100.0 - | PMID1320121 | ChEMBL |
Activity | 62.0 - | PMID7515442 | ChEMBL |
Activity | 80.0 % | PMID8496700 | ChEMBL |
Activity | 103.3 % | PMID19646882 | ChEMBL |
Activity | 106.4 % | PMID26035635, PMID21667972 | ChEMBL |
IC50 | 62.0 nM | PMID1335078, PMID1320121 | BindingDB,ChEMBL |
IC50 | 138.0 nM | PMID18039010, PMID16989522, PMID17388627, PMID17451272 | BindingDB,ChEMBL |
IC50 | 151.0 nM | PMID11585443 | BindingDB,ChEMBL |
IC50 | 1461.0 nM | DrugMatrix in vitro pharmacology data | ChEMBL |
Inhibition | 103.4 % | PMID23659286 | ChEMBL |
Ke | 35.0 nM | PMID20055417 | ChEMBL |
Ki | 17.0 nM | PMID8114680 | BindingDB |
Ki | 19.0 nM | PMID7932535 | BindingDB,ChEMBL |
Ki | 21.0 nM | PMID19527931 | BindingDB |
Ki | 21.38 nM | PMID19527931 | ChEMBL |
Ki | 30.0 nM | PMID26035635 | BindingDB,ChEMBL |
Ki | 33.0 nM | PMID18313920, PMID14643346, PMID17149859, PMID17149858 | BindingDB,ChEMBL |
Ki | 37.0 nM | PMID12747782 | BindingDB,ChEMBL |
Ki | 38.0 nM | PMID21482470 | BindingDB,ChEMBL |
Ki | 41.0 nM | PMID10741545 | BindingDB,ChEMBL |
Ki | 42.6 nM | PMID8496700 | ChEMBL |
Ki | 43.0 nM | PMID8496700 | BindingDB |
Ki | 51.0 nM | PMID20055417 | BindingDB,ChEMBL |
Ki | 63.0958 nM | PMID9686407 | IUPHAR |
Ki | 67.5 nM | PMID9686407 | BindingDB |
Ki | 76.0 nM | PMID17407276 | BindingDB,ChEMBL |
Ki | 103.0 nM | MedChemComm, (2016) 7:2:317, PMID25062506 | BindingDB,ChEMBL |
Ki | 120.0 nM | PMID19027293 | BindingDB,ChEMBL |
Ki | 141.3 nM | PMID7932177 | BindingDB |
Ki | 515.0 nM | DrugMatrix in vitro pharmacology data | ChEMBL |
Ki | 1000.0 nM | PMID7932177 | BindingDB |
Ki | 1516.0 nM | PMID25268943 | BindingDB,ChEMBL |
pKb | 7.32 - | PMID19527931 | ChEMBL |
zhanglabzhanggroup.org | (734) 647-1549 | 100 Washtenaw Avenue, Ann Arbor, MI 48109-2218